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Potent questions about cannabis and mental health
The association between cannabis use and psychosis 
is well established, with estimated odds ratios (ORs) 
of 1·4 for lifetime exposure and 2·1 for frequent use 
according to longitudinal population-based cohorts.1 
These results seem to show a dose-response effect,1 
but have not taken account of a key component 
of cannabis—its potency. In The Lancet Psychiatry, 
Marta Di Forti and colleagues2 address this gap with 
a case-control analysis of first-episode psychosis. 
Strengths of the study include the large sample of 
patients (n=410), an impressive response rate for 
participation (461 [76%] of 606 individuals) and 
appropriate control for confounding by gender, 
ethnicity, education, employment status, and other 
drug use. 
Consistent with previous reports,1 patients with first-
episode psychosis were more likely than controls to 
have used cannabis on a daily basis. More importantly, 
however, this effect was strongly dependent on the 
type of cannabis used. The investigators identified no 
associations between low-potency (hash) cannabis 
and psychosis, even with daily use. By contrast, the 
risk increased substantially for high-potency (skunk) 
cannabis, with ORs of 1·9 (95% CI 1·08–2·62) for 
use less than once per week, 2·7 (1·4–9·1) for use at 
weekends, and 5·4 (2·8–11·3) for use every day. 
These findings make a notable contribution to the 
existing literature on cannabis and psychosis. Previous 
studies1 reporting a stronger association in frequent 
users, have been unable to separate heaviness of use 
from some of its correlates. For example, as frequency 
of cannabis use rises, so does the regularity with 
which an individual carries out a stigmatised and 
widely illegal activity, which has important social and 
developmental implications. Simultaneously, time 
spent on other recreational activities, education, or 
work will typically decrease. Furthermore, cannabis 
is almost always smoked with tobacco in many 
countries, including the UK. This fact makes separation 
of the effects of tobacco co-administration from 
those of cannabis itself challenging.3 These factors 
cannot explain the differential associations between 
cannabis type and psychosis reported by Di Forti and 
colleagues,2 if skunk and hash are assumed to be used 
by similar populations in a similar manner.
Replication of these findings in longitudinal 
cohorts will be important. Ideally these studies 
should biologically quantify cannabinoid exposure 
in addition to self-reported use. These measures 
could account for individual patterns of use, such as 
titrating (using less cannabis) as potency increases.4 
Skunk is not only characterised by high concentrations 
of Δ-9-tetrahydrocannabinol (THC; about 15%), but 
also by scarcity of cannabidiol (<0·1%). By contrast, 
hash usually contains roughly 5% THC and about 4% 
cannabidiol.5 Examination of cumulative exposure 
to these cannabinoids could determine whether the 
results reported by Di Forti and colleagues might 
be explained by propsychotic effects of THC,6 anti-
psychotic effects of cannabidiol,7 or interactions 
between the two.8,9 Identification of the contribution 
of different cannabinoids might have implications for 
other mental health problems linked to cannabis, such 
as addiction.10
Di Forti and colleagues correctly state that causality 
cannot be established on the basis of their study, and 
this consideration is important. If causality exists, 
they calculate that 24% of first-episode cases in their 
South London catchment area might be attributable 
to high potency cannabis. This figure is higher than 
their estimate for daily use in general (19%). If this 
interpretation is correct, cannabis potency is more 
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important than frequency of use in prediction of risk 
of psychosis, and could have a substantial effect on 
public health. 
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